2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
22
Neoplasms
6
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Recurrence
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Cancer
4
Uveal Melanoma
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Liver Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Cystectomy
2
Cisplatin
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
tislelizumab
1
relatlimab
1
enzalutamide
1
enfortumab vedotin
1
durvalumab
1
Water
1
Urinary Diversion
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Multiparametric Magnetic Resonance Imaging
1
Microscopy
1
Immunonutrition Diet
1
Immune Checkpoint Inhibitors
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cystoscopy
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Diseases
×
relatlimab
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled